Clopidogrel Tablet, Film Coated
Product Images NDC 50090-2082

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 50090-2082). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Clopidogrel Fig1)

A horizontal bar chart showing the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite AUC of Clopidogrel Bisulfate 75 mg. Four PPIs are listed vertically—Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg—with corresponding bars representing change relative to Clopidogrel administered alone, including mean values and 90% confidence intervals.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

A line graph depicting cumulative event rates over 12 months comparing cardiovascular events (death, myocardial infarction, stroke) between two groups: placebo (+ aspirin) and Clopidogrel Bisulfate (+ aspirin). The y-axis shows cumulative event rate percentage, while the x-axis shows months of follow-up. The graph indicates a lower event rate for the Clopidogrel Bisulfate group.*

FDA Label Image

Figure-3 (Clopidogrel Fig3)

The image is a data table presenting subgroup analyses comparing Clopidogrel Bisulfate to placebo across various demographic and clinical categories (age, gender, race, enzymatic elevation, diabetes history, prior myocardial infarction or stroke, and concurrent medication use). It includes the number of subjects, event counts and percentages for each group, and hazard ratios with 95% confidence intervals depicted graphically to indicate favorability toward Clopidogrel or placebo.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

A line graph comparing the percentage of deaths before hospital discharge over time for patients receiving Clopidogrel versus a placebo. The x-axis represents days since randomization (up to 28 days), and the y-axis shows the percentage of deaths. The graph indicates a 7% proportional risk reduction in deaths with Clopidogrel compared to placebo.*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

A Kaplan-Meier curve showing the percentage of patients experiencing death, re-infarction, or stroke during the first 28 days after randomization. Two treatment groups are compared: Clopidogrel with a 9.2% event rate and placebo with a 10.1% event rate, indicating a 9% proportional risk reduction (p = 0.002) with Clopidogrel.*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

A forest plot chart comparing odds ratios with 99% confidence intervals across various subgroups including gender, age, time since onset, systolic blood pressure, heart rate, and use of fibrinolytic agents. The chart visually contrasts Clopidogrel Bisulfate against placebo for each subgroup and overall, indicating favorability toward Clopidogrel Bisulfate or placebo.*

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

A line graph showing cumulative event rates (%) of fatal or non-fatal vascular events over 36 months of follow-up. The graph compares aspirin with clopidogrel bisulfate, with two lines representing each. The aspirin line shows a higher cumulative event rate than clopidogrel bisulfate, with a reported p-value of 0.045.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

A data table comparing the effects of Clopidogrel Bisulfate and Aspirin across different qualifying conditions: Stroke, MI, and PAD. Columns show the number of patients (N), event counts and percentages for each drug, and a hazard ratio plot with confidence intervals indicating favorability toward Clopidogrel Bisulfate or Aspirin for each condition and overall outcomes.*

FDA Label Image

Chemical Structure (Clopidogrel Str)

Chemical structure of Clopidogrel Bisulfate, showing its molecular formula with marked atoms including chlorine and sulfur, consistent with the active ingredient in the prescription drug Clopidogrel 75 mg tablets by A-S Medication Solutions.*

FDA Label Image

Label Image (Lbl500902082)

Label for Clopidogrel 75 mg film-coated tablets, oral route, by A-S Medication Solutions. The label states each tablet contains 97.875 mg clopidogrel bisulfate equivalent to 75 mg clopidogrel. Packaging includes 30 tablets with storage instructions to keep at 20 to 25 degrees Celsius, protecting from moisture. The NDC is 50090-2082.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.